55
Views
1
CrossRef citations to date
0
Altmetric
Original Research

What is the role of adipokines in myasthenia gravis?

, , &
Pages 1515-1525 | Published online: 28 Aug 2018

References

  • MeriggioliMSandersDAutoimmune myasthenia gravis: emerging clinical and biological heterogeneityLancet Neurol20098547549019375665
  • WangLZhangYHeMClinical characteristics of patients with myasthenia gravis associated with other autoimmune diseasesChin J Contemp Neurol Neurosurg20141410873877
  • VincentAPalaceJHilton-JonesDMyasthenia gravisLancet20013572122212811445126
  • Rodriguez CruzPMAl-HajjarMHudaSClinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravisJAMA Neurol20157264264925894002
  • ZhangBTzartosJBelimeziMAutoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravisArch Neurol201269444545122158716
  • HiguchiOHamuroJMotomuraMYamanashiYAutoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravisAnn Neurol201169241842221387385
  • PevznerASchoserBPetersKAnti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravisJ Neurol2012259342743521814823
  • AndersenJBOweJFEngelandAGilhusNETotal drug treatment and comorbidity in myasthenia gravis: a population-based cohort studyEur J Neurol201421794895524712740
  • BalandinaALecartSDartevellePSaoudiABerrih-AkninSFunctional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravisBlood200510573574115454488
  • ThiruppathiMRowinJGaneshBShengJPrabhakarBMeriggioliMNImpaired regulatory function in circulating CD4(+)CD25(high) CD127(low/−) T cells in patients with myasthenia gravisClin Immunol201214520922323110942
  • GradolattoANazzalDTruffaultFBoth Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-αJ Autoimmun201452536324405842
  • DiezJIglesiasPThe role of the novel adipocyte-derived hormone adiponectin in human diseaseEur J Endocrinol200314829330012611609
  • ZhangDQWangRLiTRemarkably increased resistin levels in anti-AChR antibody-positive myasthenia gravisJ Neuroimmunol201528371026004149
  • AshimaRQiYSinghalNBrain adipokine action and metabolic regulationDiabetes200655145154
  • OuchiNParkerJLugusJWalshKAdipokines in inflammation and metabolic diseaseNat Rev Immunol201111859721252989
  • De SanctisJZabaletaMBiancoNGarmendiaJRivasLSerum adipokine levels in patients with systemic lupus erythematosusAutoimmunity200942427227419811274
  • ZhangMDiniAYangXAssociation between serum/plasma adiponectin levels and immune-mediated diseases: a meta-analysisArch Dermatol Res2017309862563528702765
  • LiHZhangTLengRLiXLiXPanHPlasma/serum leptin levels in patients with systemic lupus erythematosus: a meta-analysisArch Med Res201546755155626452329
  • WislowskaMRokMStepienKKuklo-KowalskaASerum leptin in systemic lupus erythematosusRheumatol Int200828546747318196243
  • AlmehedKd’EliaHBokarewaMCarlstenHRole of resistin as a marker of inflammation in systemic lupus erythematosusArthritis Res Ther200810115
  • HuangQTaoSZhangYSerum resistin levels in patients with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysisClin Rheumatol201534101713172025935455
  • ShehzadAIqbalWShehzadOLeeYSAdiponectin: regulation of its production and its role in human diseasesHormones20121182022450341
  • La CavaAMatareseGThe weight of leptin in immunityNat Rev Immunol2004437137915122202
  • FilkovaMHaluzikMGaySSenoltLThe role of resistin as a regulator of inflammation: implications for various human pathologiesClin Immunol2009133215717019740705
  • MoschenARKaserAEnrichBVisfatin, an adipokine with proinflammatory and immunomodulating propertiesJ Immunol200717831748175817237424
  • Hernández-DíazAArana-MartínezJCCarbóREspinosa-CervantesRSánchez-MuñozFOmentina: papel en la resistencia a la insulina, inflamación y protección cardiovascular [Omentin: role in insulin resistance, inflammation and cardiovascular protection]Arch Cardiol Mex201686233243 Spanish [with English abstract]26778502
  • BurnTConawayMCutterGSandersDConstruction of an efficient evaluative instrument of myasthenia gravis: the MG compositeMuscle Nerve2008381553156219016543
  • WolfeGHerbelinLNationsSFosterBBryanWBarohnRMyasthenia gravis activities of daily living profileNeurology19995271487148910227640
  • BurnsTConawayMCutterGSandersDMuscle Study GroupLess is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravisMuscle Nerve200838295796318642357
  • JaretzkiABarohnRErnstoffRMyasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of AmericaAnn Thorac Surg20007032733410921745
  • BrazNRochaNVieiraÉNegative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravisNeurol Sci20173881405141328488158
  • NatarajanRHagmanSHämälainenMAdipsin is associated with multiple sclerosis: a follow-up study of adipokinesMult Scler Int2015201537173426634156
  • GorguiJGasbarrinoKGeorgakisMCirculating adiponectin levels in relation to carotid atherosclerotic plaque presence, ischemic stroke risk, and mortality: a systematic review and meta-analysesMetabolism201769516628285652
  • RozmilowskaIAdamczyk-SowaMWhat is the role of interleukin 33 and ST2 receptor in myasthenia gravis?J Neuroimmunol2018315505729306406